VTRS Quote, Financials, Valuation and Earnings

BioCryst Pharmaceuticals, Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 8.09%. Viatris, Inc.'s return on equity of -21.75% beat BioCryst Pharmaceuticals, Inc.'s return on equity of --.

Viatris, Inc. has a consensus price target of $12.1250, signalling downside risk potential of -0.94%. On the other hand BioCryst Pharmaceuticals, Inc. has an analysts' consensus of $20.60 which suggests that it could grow by 173.57%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Viatris, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison BioCryst Pharmaceuticals, Inc. has a beta of 0.909, suggesting its less volatile than the S&P 500 by 9.061%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.92%. BioCryst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. BioCryst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than BioCryst Pharmaceuticals, Inc. quarterly revenues of $159.4M. Viatris, Inc.'s net income of -$128.2M is lower than BioCryst Pharmaceuticals, Inc.'s net income of $12.9M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while BioCryst Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.03x versus 2.77x for BioCryst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 14.91%. Viatris, Inc.'s return on equity of -21.75% beat Boston Scientific Corp.'s return on equity of 12.46%.

Viatris, Inc. has a consensus price target of $12.1250, signalling downside risk potential of -0.94%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 30.98%. Given that Boston Scientific Corp. has higher upside potential than Viatris, Inc., analysts believe Boston Scientific Corp. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.92%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Viatris, Inc.'s net income of -$128.2M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 51.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.03x versus 7.42x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of -19.69%. Viatris, Inc.'s return on equity of -21.75% beat Moderna, Inc.'s return on equity of -30.18%.

Viatris, Inc. has a consensus price target of $12.1250, signalling downside risk potential of -0.94%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 12.21%. Given that Moderna, Inc. has higher upside potential than Viatris, Inc., analysts believe Moderna, Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.92%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than Moderna, Inc. quarterly revenues of $1B. Viatris, Inc.'s net income of -$128.2M is higher than Moderna, Inc.'s net income of -$200M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.03x versus 5.68x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 21.32%. Viatris, Inc.'s return on equity of -21.75% beat Pfizer Inc.'s return on equity of 10.84%.

Viatris, Inc. has a consensus price target of $12.1250, signalling downside risk potential of -0.94%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Pfizer Inc. has higher upside potential than Viatris, Inc., analysts believe Pfizer Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.92%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Viatris, Inc. quarterly revenues are $3.8B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Viatris, Inc.'s net income of -$128.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.03x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.